Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (12313)	7/31/1998 1:13:00 AM
From: AlienTech	Read Replies (2) \| Respond to of 23519

What the hell happened to yahoo? Seems like the shorts are out in a dizzy. Must be a full moon.

To: Mkilloran who wrote (12313)	7/31/1998 8:31:00 AM
From: ChinuSFO	Read Replies (1) \| Respond to of 23519

<< .....do you think the part about ASTRA combined with MERCK and how ASTRA may BUY or Merge with other US companies?????? Maybe ones that they already deal with like VIVUS????? >> That has been the speculation all along after it was announced about 8 weeks ago that Astra was looking to pull out of the ASTRA-MERCK deal since it prevented ASTRA from gaining a larger share of the US market. Hence ASTRA pulls out of the deal and starts acquiring US companies to increase their US market involvement. And guess whom they find right at their doorstep? So the likely scenarios are: a. ASTRA or J&J buyout b. J&J or ALZA partnership

To: Mkilloran who wrote (12313)	7/31/1998 9:20:00 AM
From: betty moyers	Respond to of 23519

Here's the comments on acq/merger by Astra How does one read this?? Immediate interest in acquistion or a decade from now?? Mogren declined to comment on what plans the company has for expansion. On June 19, Astra said it would buy Merck & Co.'s 50 percent of its U.S. marketing joint venture for a minimum $4.4 million. The acquisition will be completed no sooner than 2008, paving the way for a merger or acquisition. ''We are looking at many possibilities for expansion and we don't have the limitations set by the Merck deal anymore,'' said Mogren. He declined to be more specific. Pharmaceutical makers worldwide have been seeking combinations to boost research and reduce costs as governments and health insurers demand lower prices.